USE OF A CD8+ T CELL INHIBITORY AGENT IN THE PRESENCE OF A CD4+ T CELL INHIBITORY AGENT FOR INHIBITION OF TRANSPLANT REJECTION

摘要

The invention relates generally to the treatment, inhibition or prevention of immune-driven rejection of grafted tissue or cells in a recipient host. Compositions and methods disclosed herein capitalize on the discovery that treatment, inhibition or prevention of costimulation blockade-resistant rejection can be mediated by administering a pharmaceutically effective amount of a CD8+ T cell inhibitory agent in the presence of a CD4+ T cell inhibitory agent to a subject.